Compare · ABSI vs IQV
ABSI vs IQV
Side-by-side comparison of Absci Corporation (ABSI) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $30.66B, about 30.0x ABSI ($1.02B).
- Over the past year, ABSI is up 116.2% and IQV is up 20.1% - ABSI leads by 96.2 points.
- ABSI has been more active in the news (10 items in the past 4 weeks vs 5 for IQV).
- IQV has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- IQVIA Holdings Inc.
- Price
- $6.39-2.29%
- $184.97+0.70%
- Market cap
- $1.02B
- $30.66B
- 1M return
- +8.57%
- +3.60%
- 1Y return
- +116.22%
- +20.05%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2013
- News (4w)
- 10
- 5
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest ABSI
- Director Szela Mary T was granted 10,100 shares (SEC Form 4)
- Director Pangalos Menelas N was granted 10,100 shares, increasing direct ownership by 4% to 242,408 units (SEC Form 4)
- Director Van Houten Frans was granted 10,100 shares, increasing direct ownership by 16% to 73,420 units (SEC Form 4)
- Director Rabinovitsj Daniel A was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)
- Director Sirosh Joseph was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)
- Absci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Leerink Partners initiated coverage on Absci Corporation with a new price target
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,319 shares, decreasing direct ownership by 2% to 491,464 units (SEC Form 4) to satisfy withholding tax
- BTIG Research initiated coverage on Absci Corporation with a new price target
- Absci to Participate in Upcoming Investor Conferences
Latest IQV
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Offering of Senior Notes
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G